Cloning Techniques Create Embryonic Stem Cells

Join Our Community of Science Lovers!

On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.

Researchers from Memorial Sloan-Kettering Cancer Center and the Rockefeller University have taken an important step toward developing new treatments for Parkinson's disease and a host of other ailments, using techniques from cloning to create embryonic stem cells in the lab. These cells have the remarkable ability to grow into any replacement body part, be it bone, skin, blood or brain. Thus, by cloning a patient's own stem cells and growing them into needed tissues, scientists hope to avoid the common problem of transplant rejection. "This was the very first step in showing this kind of therapy might work," says Sloan-Kettering scientist Lorenz Studer, senior author on a paper that appeared in Science on Friday.

The researchers took cells from the tail of one mouse and transferred the nuclei from those cells into another mouse's oocytes, which had been emptied of their own nuclei. This kind of nuclear transfer is the first step in cloning an entirely new animal. After a few days of development, however, the researchers removed the embryonic stem cells and then coaxed them into becoming brain cells that make the neurotransmitter dopamine. It is this type of neuron that patients with Parkinson's disease slowly lose.

"These are a very specialized cell type," Studer explains. "Even within the fully developed brain, only about 1 in 100,000 cells are midbrain dopamine neurons, so it's quite a feat to be able to generate them." Scientists had previously created dopamine neurons only from hard-to-access fetal brain stem cells. With a grant from the Michael J. Fox Foundation, Studer now plans to take the experiment further: he will clone embryonic stem cells from mice with Parkinson's, generate genetically matched dopamine neurons and then transplant those cells back into the mice, hoping it will treat the disease.

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American